ASTHMA/ALLERGY

Cost Studies 

PAA1

CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND BUDGET IMPACT ANALYSIS

Kaczor M, Becla L, Wojcik R, Dardzinski W, Walczak J, Nogas G

Arcana Institute, Cracow, Poland

PAA2

EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA: RESULTS FROM THE SIMAP DATABASE STUDY

Berto P¹, Bassi M², Cadario G³, Cantarutti L⁴, Contiguglia R⁵, Crivellaro M⁶, Di Gioacchino M⁷, Frati F⁸, Magazzù C⁵, Marengo F³, Scamarcia A⁴, Schiappoli M⁶, Valle C⁹, Verna N⁷, Giaquinto C¹⁰

¹Pbe consulting, Verona, Italy, ²Rho Hospital, Cerchiate di Pero (MI), Italy, ³Azienda Ospedaliera S.Giovanni Battista di Torino (Molinette), Torino, Italy, ⁴SOSEPE, Padova, Italy, ⁵AUSL 5, Messina, Italy, ⁶Azienda Ospedaliera Verona, Verona, Italy, ⁷D'Annunzio University, Chieti, Italy, ⁸Stallergenes Italy, Milano, Italy, ⁹Ospedale San Paolo, Milano, Italy, ¹⁰University of Padova, Padova, Veneto, Italy

PAA3

COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/ BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

Orlewska E¹, Cel M², Glogowski C²

¹Centrum Farmakoekonomiki, Warsaw, Poland, ²GSK Commercial Sp. z o.o, Warsaw, Poland

PAA4

PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS

Kulikov A, Lomakin A, Krysanov I, Polivanov V

Moscow Medical Academy, Moscow, Russia

PAA5

ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

Berg J¹, Lindgren P¹, Jönsson B²

¹Stockholm Health Economics, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Sweden

PAA6

VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE EVENTS: COMPARISON OF CICLESONIDE WITH FLUTICASONE PROPIONATE

Wlodarczyk JH¹, Harvey C², Caeser M³

¹John Wlodarczyk Consulting Services, New Lambton, NSW, Australia, ²Altana Pharma Pty Ltd, NOrth Ryde, NSW, Australia, ³ALTANA Pharma AG, Konstanz, Germany

PAA7

ANALYZING THE INFLUENCE OF SWITCHING BETWEEN DIFFERENT ASTHMA REGIMES ON MEDICATION ADHERENCE TO ASTHMA THERAPY, RESOURCE UTILIZATION AND COSTS

Buesch K¹, Welte R², Singer C²

¹GSF-National Research Center for Environment and Health, Neuherberg, Bavaria, Germany, ²GlaxoSmithKline, Munich, Germany

PAA8

A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS

Ciobanu A

AstraZeneca, Mississauga, ON, Canada

Health Care Use & Policy Studies

PAA9

THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE

Fung V¹, Fireman B¹, Brand R², Newhouse JP³, Hsu J¹

¹Kaiser Permanete, Oakland, CA, USA, ²University of California at San Francisco, San Francisco, CA, USA, ³Harvard University, Boston, MA, USA

PAA10

HEALTH PLAN STRUCTURE AND EXPENDITURES FOR ASTHMA CARE

Nurmagambetov T, Atherly A, Williams S, Redd S

Centers for Disease Control and Prevention, Atlanta, GA, USA

Methods & Concepts

PAA11

COST-EFFECTIVENESS ANALYSIS FOR THE ASSESSMENT OF PREVENTIVE SCHEMES BASED ON GENETIC SCREENING

Gutierrez de Mesa E¹, Hidalgo I¹, Christidis P¹, Ciscar JC¹, Vegas E², Ibarreta D¹

¹Institute for Prospective Technological Studies, JRC-European Commission, seville, Spain, Spain, ²Servicio Madrleño de Salud, Alcala de Henares. MADRID, Spain

Patient Reported Outcomes 

PAA12

THE EFFECT OF SWITCHING ON ADHERENCE TO DIFFERENT TYPES OF ASTHMA TREATMENT

Buesch K¹, Singer C², Welte R²

¹GSF-National Research Center for Environment and Health, Neuherberg, Bavaria, Germany, ²GlaxoSmithKline, Munich, Germany

PAA13

OBTAINING POPULATION REFERENCE VALUES FOR THE ESPRINT-15 QUESTIONNAIRE, A SPECIFIC QUALITY OF LIFE SCALE FOR ALLERGIC RHINITIS (AR)

Valero A¹, Monclús L², Baro E³, on behalf of Esprint Study Investigators -⁴

¹Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, ²J. Uriach & Cia, S.A, Palau-solità i plegamans, Barcelona, Spain, ³3D Health Research, Barcelona, Spain, ⁴Esprint Study Investigators, Spain, Spain

PAA14

PATIENT-PERCEIVED SIDE EFFECTS OF CICLESONIDE AS COMPARED TO FLUTICASONE PROPIONATE IN THE TREATMENT OF MODERATE ASTHMA USING THE INHALED CORTICOSTEROID QUESTIONNAIRE

van der Molen T¹, Leichtl S², Caeser M²

¹University of Groningen, Groningen, The Netherlands, ²ALTANA Pharma AG, Konstanz, Germany

PAA15

THE CONSTRUCT VALIDITY AND TEST-RETEST RELIABILITY OF THE INHALED CORTICOSTEROID QUESTIONNAIRE (ICQ): A PATIENT SELF-REPORTED SIDE EFFECT SCALE

Foster JM¹, Van Sonderen E¹, Lee AJ², Sanderman R¹, Van der Molen T¹

¹University of Groningen, Groningen, The Netherlands, ²University of Aberdeen, Aberdeen, UK

CARDIOVASCULAR

Clinical Outcomes Studies

PCV1

CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE

Scranton R¹, Dhingra R¹, Lawler E², Hay JW³, Yucel K², Guo A⁴, Balzer T⁴, Gaziano J¹

¹VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA, ²VA Boston Healthcare System, Boston, MA, USA, ³University of Southern California, Los Angeles, CA, USA, ⁴Berlex Laboratories, Wayne, NJ, USA

PCV2

CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

McCollam PL¹, Nasuti P², Bae JP¹, Smith H²

¹Eli Lilly and Company, Indianapolis, IN, USA, ²IMS Hospital Group Ltd, Sittingbourne, UK

PCV3

DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE ?

Pietrasik A¹, Starczewska M¹, Glowczynska R¹, Opolski G¹, Filipiak KJ¹, Jakubczyk M², Niewada M¹, Latek M³

¹Medical University of Warsaw, Warsaw, Poland, ²Warsaw School of Economics, Warsaw, Poland, ³Warsaw School of Economics, Warszawa, Poland

PCV4

META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF PRESSURE MEASUREMENTS IN CORONARY ARTERY DISEASE

Bornschein B¹, Klauss V², Siebert U¹

¹UMIT University of Health Sciences, Medical Informatics, and Technology, Hall i. T, Austria, ²University of Munich, Munich, Germany

PCV5

DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES

Eisenstein EL, Tuttle RH, Shaw LK, Anstrom KJ, Kong DF

Duke Clinical Research Institute, Durham, NC, USA

PCV6

REACHING SIGN CHOLESTEROL TARGETS AND BEYOND: RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN A SCOTTISH GENERAL PRACTICE

Burnett GR¹, Dickson K¹, Emmas CE²

¹Princes Street Surgery, Thurso, Scotland, UK, ²AstraZeneca UK, Luton, UK

PCV7

REACHING AWMSG TARGETS AND BEYOND-A RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN WELSH GENERAL PRACTICE

Moore RP¹, Chapman JR¹, Davies EJ¹, Davies SH¹, Davies N¹, Harfoot DA¹, Emmas CE²

¹Towers Surgery, Barry, Wales, UK, ²AstraZeneca UK, Luton, UK

PCV8

THE EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH OTHER STATINS – RESULTS FROM A ROUTINE CLINICAL PRACTICE SETTING IN THE UK

Hirsch MW¹, O'Donnell JC¹, Jansen JP²

¹AstraZeneca Ltd, Macclesfield, Cheshire, UK, ²Mapi Values, Houten, The Netherlands

PCV9

NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE

Breekveldt-Postma NS¹, Siiskonen SJ¹, Penning-van Beest FJ¹, Falvey H², Vincze G², Erkens JA¹, Herings RM¹

¹PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, ²Novartis Pharma AG, Basel, Switzerland

PCV10

COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR HYPERTENSION: AN OPEN RANDOMISED CONTROLLED TRIAL

Martikainen JA¹, Kastarinen M², Puska P³, Nissinen A³

¹Centre for Pharmaceutical Policy and Economics (CEPPE), Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ²Kuopio University Hospital, PL 1777, Kuopio, Finland, ³National Public Health Institute, 00300, Helsinki, Finland

PCV11

CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT.

Kawalec P¹, Borek E²

¹Jagiellonian University, Kraków, Poland, ²Astra Zeneca Poland, Warsaw, Poland

PCV12

Withdrawn

PCV13

EFFECT OF ABSOLUTE REDUCTION IN LDL CHOLESTEROL ON CARDIOVASCULAR EVENTS: DOES FINAL LDL CHOLESTEROL ACHEIVED MATTER?

Rahilly CR¹, Gaziano J², Scranton R²

¹Boston VA Healthcare System, Jamaica Plain, MA, USA, ²VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA

PCV14

ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN

Sicras A¹, F Bobadilla J², Moreno R³, Arístegui R², García M⁴

¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Madrid, Spain, ⁴Euroclin Institute, Alcobendas, Madrid, Spain

PCV15

ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)

Brixner D¹, Maio V²

¹The University of Utah College of Pharmacy, Salt Lake City, UT, USA, ²Thomas Jefferson University, Philadelphia, PA, USA

PCV16

MAIN CARDIOVASCULAR RISK FACTORS: ASSOCIATION AND CONTROL IN A PRIMARY HEALTHCARE SETTING

Sicras A¹, Navarro R¹, Rejas J², F Bobadilla J², García M³, González P²

¹Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³Euroclin Institute, Alcobendas, Madrid, Spain

PCV17

PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES

Liens D¹, Palmer AJ², Valentine WJ², Renaudin C¹, Roze S²

¹Merck Santé, Lyon, France, ²CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

PCV18

OUTCOME OF THIAZOLIDINEDIONE USE IN DISCHARGED DIABETIC PATIENTS WHO WERE HOSPITALIZED FOR HEART FAILURE

Chou HY¹, Huang WF², Tsai YW³

¹National Yang-Ming University, Taipei City, Taiwan, ²National Yang-Ming University, Taipei, Taiwan, ³National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan

PCV19

DISCONTINUED USE OF MYCOPHENOLATE MOFETIL AND GRAFT LOSS IN HEART TRANSPLANT RECIPIENTS

Legorreta AP¹, Kang N² , Gilmore AS², Marehbian J², Naujoks C³ , Machnicki G³

¹UCLA School of Public Health, Los Angeles, CA, USA, ²Health Benchmarks, Inc, Woodland Hills, CA, USA, ³Novartis Pharma AG, Basel, Switzerland

Cost Studies

PCV20

FINANCIAL IMPACT OF EPLERENONE USE IN A SPANISH REFERENCE HOSPITAL

F Bobadilla J¹, García M²

¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Euroclin Institute, Alcobendas, Madrid, Spain

PCV21

ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK

Blak BT¹, Weir MR¹, Simoni-Wastila L¹, Shaya FT¹, Cooke CE², Mullins CD¹

¹University of Maryland, Baltimore, MD, USA, ²Pfizer Inc, Ellicott City, MD, USA

PCV22

COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)

Hay JW¹, Scranton R², Yucel K³, Guo A⁴, Balzer T⁴, Gaziano J²

¹University of Southern California, Los Angeles, CA, USA, ²VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA, ³VA Boston Healthcare System, Boston, MA, USA, ⁴Berlex Laboratories, Wayne, NJ, USA

PCV23

ECONOMIC BURDEN OF CONTRAST-INDUCED NEPHROPATHY (CIN): IMPLICATIONS FOR PREVENTION STRATEGIES

Subramanian S¹, Bapat B², Zyczynski T³, Tumlin J⁴

¹RTI International, Waltham, MA, USA, ²RTI Interntional, Research Triangle Park, NC, USA, ³GE Healthcare, Princeton, NJ, USA, ⁴University of NC and Southeast Renal Associates, Charlotte, NC, USA

PCV24

CARDIOVASCULAR EVENTS REDUCTION AND COST-EFFECTIVENESS OF ATORVASTATIN VERSUS PRAVASTATIN IN SPANISH POPULATION WITH ACUTE CORONARY SYNDROME (ACS)

F Bobadilla J¹, Checa JC¹, Soto J¹, García M², Martínez E¹, Hernández G¹

¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Euroclin Institute, Alcobendas, Madrid, Spain

PCV25

COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: WITHIN TRIAL ANALYSIS

Jerjes-Sanchez C¹, Trujillo A², Ramos MA³, Hernandez I⁴, Alvarado R⁵, Cruz A⁶, Rangel FJ⁶, Morales E⁷

¹Hospital de Enfermedades Cardiovasculares y Torax-IMSS, Monterrey, Nuevo León, Mexico, ²Hospital General de Zona 57, Tlalnepantla, Mexico, Mexico, ³UMAE CM La Raza, Mexico City, Mexico City, Mexico, ⁴Hospital Juarez de Mexico, Mexico City, Mexico, Mexico, ⁵ISSSTE Durango, Durango, Durango, Mexico, ⁶Hospital PEMEX-Norte, Mexico City, Mexico City, Mexico, ⁷Cardiometabolic Research Unit, Aguascalientes, Aguascalientes, Mexico

PCV26

COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: A LONG TERM ANALYSIS

Jerjes-Sanchez C¹, Trujillo A², Ramos MA³, Hernandez I⁴, Alvarado R⁵, Cruz A⁶, Rangel FJ⁶, Morales E⁷

¹Hospital de Enfermedades Cardiovasculares y Torax-IMSS, Monterrey, Nuevo León, Mexico, ²Hospital General de Zona 57, Tlalnepantla, Mexico, Mexico, ³UMAE CM La Raza, Mexico City, Mexico, ⁴Hospital Juarez de Mexico, Mexico City, Mexico, ⁵ISSSTE Durango, Durango, Mexico, ⁶Hospital PEMEX-Norte, Mexico City, Mexico, ⁷Cardiometabolic Research Unit, Aguascalientes, Mexico

PCV27

COST-EFFECTIVENESS OF BETALOC COMPARED TO CARVEDILOL IN CARDIAC INSUFFICIENCY AND ARTERIAL HYPERTENSION TREATMENT IN POLAND

Kawalec P¹, Borek E²

¹Jagiellonian University, Kraków, Poland, ²Astra Zeneca Poland, Warsaw, Poland

PCV28

COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY

Taylor DC¹, Pandya A¹, Thompson D¹, Chu P¹, Graff J², LaRosa JC³, Grundy SM⁴, Wenger NK⁵, Shepherd J⁶, Drummond MF⁷

¹i3 Innovus, Medford, MA, USA, ²Pfizer, Inc, New York, NY, USA, ³State University of New York Health Science Center, Brooklyn, NY, USA, ⁴University of Texas, Dallas, TX, USA, ⁵Emory University School of Medicine, Atlanta, GA, USA, ⁶University of Glasgow, Glasgow, Scotland, UK, ⁷University of York, York, Heslington, UK

PCV29

COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN TREATING PATIENTS TO LDL-C ATP III GOALS. A MEXICAN PERSPECTIVE OF THE STELLAR TRIAL.

Soto H¹, Mino D², Polanco AC¹, Gomez G³, Miller P⁴

¹Astra Zeneca, Naucalpan, Estado de México, Mexico, ²Instituto Mexicano de Seguro Social, México D.F, México, Mexico, ³Hospital General Dr. Manuel Gea Gonzalez, México D.F, México D.F, Mexico, ⁴Astra Zeneca, Alderley Park, Alderley Park, UK

PCV30

COST-EFFECTIVENESS OF ROSUVASTATIN FOR CARDIOVASCULAR PREVENTION IN HIGH-RISK POPULATIONS IN SWEDEN

Jönsson L¹, Ekman M², Karlsson G³, Brun J³

¹European Health Economics, London, UK, ²Stockholm Health Economics, Stockholm, Sweden, ³AstraZeneca, Södertälje, Sweden

PCV31

HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES: AN ANALYSIS FOR SWEDEN

Renaudin C¹, Liens D¹, Palmer AJ², Valentine WJ², Berger W³, Roze S²

¹Merck Santé, Lyon, France, ²CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, ³Merck KGaA, Darmstadt, Germany

PCV32

COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: EUROPEAN MODEL RESULTS BASED ON CLARITY AND COMMIT

Berg J¹, Lindgren P¹, Jönsson B²

¹Stockholm Health Economics, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Sweden

PCV33

COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM

Rodríguez J¹, Caro JJ², Roda J³, Ward A², Xenakis J², Malik F⁴, Bariz H²

¹Medtronic Iberia, Madrid, Spain, ²Caro Research Institute, Concord, MA, USA, ³General Valencia University Hospital, Valencia, Spain, ⁴Medtronic Sarl, Tolochenaz, Laussane, Switzerland

PCV34

A COST-EFFECTIVENESS ANALYSIS OF OLMESARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION

Lamotte M¹, Annemans L², Van Loy R³, Koch W⁴

¹IMS Health, Brussel, Brabant, Belgium, ²IMS Health, Brussels, Belgium, ³Sankyo Pharma, Louvain-La-Neuve, Brabant, Belgium, ⁴HaaPACS GmbH, Schriesheim, Schriesheim, Germany

PCV35

ESTIMATING LIFETIME COSTS AND LIFE EXPECTANCY ASSOCIATED WITH CARDIOVASCULAR DISEASE IN A SWISS POPULATION WITH AND WITHOUT METABOLIC SYNDROME

Ray J¹, Darioli R², Roze S³, Azoulay M⁴, Bernhardt M⁴, Valentine WJ⁵

¹IMS Health, Allschwil, Basel, Switzerland, ²Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, ⁴sanofi-aventis (suisse) sa, Meyrin, Geneva, Switzerland, ⁵CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland

PCV36

A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION

Lamotte M¹, Annemans L², Siebert M³

¹IMS Health, Brussel, Brabant, Belgium, ²IMS Health, Brussels, Belgium, ³St-Jude Medical, Zaventem, Vlaams Brabant, Belgium

PCV37

COST-EFFECTIVENESS OF LONG-TERM TREATMENT OF HYPERTENSION WITH IRBESARTAN VS. LOSARTAN OR NO TREATMENT IN DENMARK

Knudsen MS¹, Lange M², Dahl E³

¹Muusmann Research & Consulting AS, Copenhagen, Denmark, ²Sanofi-aventis, Hoersholm, Denmark, ³Bristol-Myers Squibb, Lyngby, Denmark

PCV38

COST MINIMIZATION ANALYSIS OF BIVALIRUDIN VERSUS HEPARIN PLUS PLANNED ABXICIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Cequier Á¹, Morís C², Badia X³, Lara N³

¹Hospital Universitario de Bellvitge. Universidad de Barcelona, Barcelona, Barcelona, Spain, ²Hospital Universitario Central de Asturias, Asturias, Asturias, Spain, ³Health Outcomes Research Europe, Barcelona, Spain

PCV39

PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

Berto P¹, Cremonesi G²

¹Pbe consulting, Verona, Italy, ²Chiesi Farmaceutici, Parma, Italy

PCV40

A COST-EFFECTIVENESS ANALYSIS OF CARDIAC REHABILITATION AFTER PERCUTANEOUS CORONARY INTERVENTIONS

Lamotte M¹, Annemans L², Raskin A³, Hansen D³, Dendale P³

¹IMS Health, Brussel, Brabant, Belgium, ²IMS Health, Brussels, Belgium, ³Virga Jesse Hospital, Hasselt, Limburg, Belgium

PCV41

A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND

Shepherd J¹, Kingslake SL²

¹University of Glasgow, Glasgow, Scotland, UK, ²AstraZeneca UK Ltd, Luton, Bedfordshire, UK